Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan invests $20m in Proteostasis and agrees a further $30m in funding

This article was originally published in Scrip

Executive Summary

Elan, which just raised $500 million by divesting its formulation and manufacturing business Elan Drug Technologies (EDT), is investing $20 million in Proteostasis Therapeutics of the US as part of a drug discovery partnership focused on small molecules to treat neurodegenerative disorders including Parkinson's disease and Alzheimer's disease.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel